Ponni V Perumalswami
Overview
Explore the profile of Ponni V Perumalswami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1061
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Perumalswami P, Belemkoabga A, Joseph L, Erblich J, Jandorf L
Hepatol Commun
. 2023 Jun;
7(6).
PMID: 37267200
Background: Applying theoretically informed constructs using an adaptation of the "Theory of Planned Behavior," this study assessed social-cognitive and sociocultural determinants of HBV screening among West Africans living in the...
12.
Rocha C, Doyle E, Bowman C, Fiel M, Stueck A, Goossens N, et al.
Cancer Med
. 2023 Apr;
12(9):10175-10186.
PMID: 37078924
Background: Successful treatment of hepatitis C reduces liver inflammation and fibrosis; however, patients remain at risk of developing hepatocellular carcinoma (HCC). Aims: To identify risk factors for new-onset HCC in...
13.
The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration
Perumalswami P, Kilpatrick S, Frost M, Adams M, Kim H, Zhang L, et al.
Addiction
. 2023 Feb;
118(6):1062-1071.
PMID: 36738085
Background And Aims: The COVID-19 pandemic disrupted health-care provision in the United States and prompted increases in telehealth-delivery of care. This study measured alcohol use disorder (AUD) treatment trends across...
14.
Perumalswami P, Wyatt B, Bowman C, Patel K, Mageras A, Lewis S, et al.
Cancer Med
. 2022 Mar;
11(9):1995-2005.
PMID: 35261196
Background: Hepatocellular carcinoma (HCC) incidence and mortality vary by race/ethnicity and both are higher in Black patients than in Whites. For HCC surveillance, all cirrhotic patients are advised to undergo...
15.
Wyatt B, Perumalswami P, Mageras A, Miller M, Harty A, Ma N, et al.
Hepatology
. 2021 Aug;
74(6):2974-2987.
PMID: 34333777
Background And Aims: Although chronic HCV infection increases mortality, thousands of patients remain diagnosed-but-untreated (DBU). We aimed to (1) develop a DBU phenotyping algorithm, (2) use it to facilitate case...
16.
Talal A, Jaanimagi U, Davis K, Bailey J, Bauer B, Dharia A, et al.
J Subst Abuse Treat
. 2021 Jun;
127:108421.
PMID: 34134875
Although hepatitis C virus (HCV) infection has high prevalence and incidence in persons with opioid use disorder (PWOUD), their engagement in HCV care has been limited due to a variety...
17.
Patel A, Bui A, Prohl E, Bhattacharya D, Wang S, Branch A, et al.
Hepatol Commun
. 2021 Mar;
5(3):371-386.
PMID: 33681673
New therapies offer hope for a cure to millions of persons living with hepatitis C virus (HCV) infection. HCV elimination is a global goal that will be difficult to achieve...
18.
Da B, Kushner T, El Halabi M, Paka P, Khalid M, Uberoi A, et al.
Hepatol Commun
. 2020 Nov;
5(2):177-188.
PMID: 33230491
Liver injury is commonly seen in coronavirus disease 2019 (COVID-19); however, the mechanism behind liver injury, particularly in patients with severe and critical COVID-19, remains unclear, and the clinical course...
19.
Marjot T, Moon A, Cook J, Abd-Elsalam S, Aloman C, Armstrong M, et al.
J Hepatol
. 2020 Oct;
74(3):567-577.
PMID: 33035628
Background & Aims: Chronic liver disease (CLD) and cirrhosis are associated with immune dysregulation, leading to concerns that affected patients may be at risk of adverse outcomes following SARS-CoV-2 infection....
20.
Rabiee A, Sadowski B, Adeniji N, Perumalswami P, Nguyen V, Moghe A, et al.
Hepatology
. 2020 Sep;
72(6):1900-1911.
PMID: 32964510
Background And Aims: Coronavirus disease 2019 (COVID-19) is associated with liver injury, but the prevalence and patterns of liver injury in liver transplantation (LT) recipients with COVID-19 are open for...